Skip to content

A prospective, multicenter, controlled, real-world clinical study of Tiaoshen Xuanluo Changmo formula combined with abdominal external application to improve endometrial blood flow after TCRA

A prospective, multicenter, controlled, real-world clinical study of Tiaoshen Xuanluo Changmo formula combined with abdominal external application to improve endometrial blood flow after TCRA

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006497
Enrollment
Unknown
Registered
2022-08-15
Start date
2022-08-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intrauterine adhesion after TCRA of Kidney deficiency and blood stasis type

Interventions

control group:Tiaoshen xuanluo Changmu formula
Test group:Tiaoshen xuanluo Changmu formula combined with abdominal external application

Sponsors

Yunnan Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1) Married female, aged 20-40 (including 20 and 40); 2) Body mass index (BMI) 18-26 (kg/m2) (including boundary value); 3) Meet the diagnostic criteria of Western medicine IUA and traditional Chinese medicine kidney deficiency and blood stasis syndrome; 4) After TCRA; 5) Good compliance, willing to participate in and cooperate with researchers to complete the study; 6) The nature, significance, possible benefits, possible inconvenience and potential risks and discomfort of the trial have been understood in detail before the trial, and they have voluntarily participated in the clinical trial and signed a written informed consent.

Exclusion criteria

Exclusion criteria: 1) Those who do not meet the above diagnostic criteria; 2) Those aged 40 years; 3) Body mass index (BMI) 26 (kg/m2); 4) Adhesion of cervical canal; 5) Menorrhagia caused by other diseases; 6) Congenital malformation of reproductive organs (such as uterine mediastinum, residual horn uterus, etc.); 7) Organic diseases of reproductive system (such as tuberculosis of reproductive system); 8) Patients with serious cardiovascular, cerebrovascular, liver, kidney and other major organ diseases; 9) Those who have taken hormone or similar traditional Chinese medicine treatment 1 month (30 days) before administration; 10) Those who are known to be allergic to the study drug (including the excipients of the study drug) or its analogues, or those with allergic constitution (such as those who are allergic to two or more drugs, food and pollen).

Design outcomes

Primary

MeasureTime frame
TCM clinical symptom score;

Secondary

MeasureTime frame
Endometrial blood flow parameters(PI\RI\S/D);Endometrial thickness;

Countries

China

Contacts

Public ContactLijuan Jiang
Jianglijuan0825@163.com13668781266

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026